Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Dearnaley

Showing results (51-60 of 148) with videos related to

Pageof 15
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|May 23, 2003
A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancerFrancesca M Buffa, Glenn D Flux, Matt J Guy, et al.
Technical Innovations & Patient Support in Radiation Oncology|February 26, 2020
Linking CHHiP prostate cancer RCT with GP records: A study proposal to investigate the effect of co-morbidities and medications on long-term symptoms and radiotherapy-related toxicityAgnieszka Lemanska, Rachel C Byford, Ana Correa, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 27, 2007
Outcome of early detection and radiotherapy for occult spinal cord compressionRamachandran Venkitaraman, Yolanda Barbachano, David P Dearnaley, et al.
The British Journal of Radiology|January 3, 2018
Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapyAna M Denis-Bacelar, Sarah J Chittenden, V Ralph McCready, et al.
European Urology|December 20, 2008
A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillanceNicholas J van As, Nandita M de Souza, Sophie F Riches, et al.
European Urology|March 12, 2013
Medium-term outcomes of active surveillance for localised prostate cancerElizabeth D Selvadurai, Mausam Singhera, Karen Thomas, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 22, 2005
The impact of introducing intensity modulated radiotherapy into routine clinical practiceElizabeth A Miles, Catharine H Clark, M Teresa Guerrero Urbano, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 5, 2006
Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397)Stephen A Mangar, Matthew R Sydes, Helen L Tucker, et al.
International Journal of Radiation Oncology, Biology, Physics|August 5, 2021
Impact of Pelvic Radiation Therapy for Prostate Cancer on Global Metabolic Profiles and Microbiota-Driven Gastrointestinal Late Side Effects: A Longitudinal Observational StudyMiguel R Ferreira, Caroline J Sands, Jia V Li, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 30, 2004
Questionnaire based quality assurance for the RT01 trial of dose escalation in conformal radiotherapy for prostate cancer (ISRCTN 47772397)W Philip M Mayles, A Rollo Moore, Edwin G A Aird, et al.
Pageof 15

Showing results (51-60 of 148) with videos related to

Sort By:
Pageof 15
European Journal of Nuclear Medicine and Molecular Imaging|May 23, 2003
A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancerFrancesca M Buffa, Glenn D Flux, Matt J Guy, et al.
Technical Innovations & Patient Support in Radiation Oncology|February 26, 2020
Linking CHHiP prostate cancer RCT with GP records: A study proposal to investigate the effect of co-morbidities and medications on long-term symptoms and radiotherapy-related toxicityAgnieszka Lemanska, Rachel C Byford, Ana Correa, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 27, 2007
Outcome of early detection and radiotherapy for occult spinal cord compressionRamachandran Venkitaraman, Yolanda Barbachano, David P Dearnaley, et al.
The British Journal of Radiology|January 3, 2018
Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapyAna M Denis-Bacelar, Sarah J Chittenden, V Ralph McCready, et al.
European Urology|December 20, 2008
A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillanceNicholas J van As, Nandita M de Souza, Sophie F Riches, et al.
European Urology|March 12, 2013
Medium-term outcomes of active surveillance for localised prostate cancerElizabeth D Selvadurai, Mausam Singhera, Karen Thomas, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 22, 2005
The impact of introducing intensity modulated radiotherapy into routine clinical practiceElizabeth A Miles, Catharine H Clark, M Teresa Guerrero Urbano, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 5, 2006
Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397)Stephen A Mangar, Matthew R Sydes, Helen L Tucker, et al.
International Journal of Radiation Oncology, Biology, Physics|August 5, 2021
Impact of Pelvic Radiation Therapy for Prostate Cancer on Global Metabolic Profiles and Microbiota-Driven Gastrointestinal Late Side Effects: A Longitudinal Observational StudyMiguel R Ferreira, Caroline J Sands, Jia V Li, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 30, 2004
Questionnaire based quality assurance for the RT01 trial of dose escalation in conformal radiotherapy for prostate cancer (ISRCTN 47772397)W Philip M Mayles, A Rollo Moore, Edwin G A Aird, et al.
Pageof 15